# FDA 483 - Sumitomo Dainippon Pharma Co., Ltd. - April 16, 2019

Source: https://www.keypedia.com/records/483/sumitomo-dainippon-pharma-co-ltd/673ad617-6525-4220-b21a-6475356ffdb9

> FDA 483 for Sumitomo Dainippon Pharma Co., Ltd. on April 16, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Sumitomo Dainippon Pharma Co., Ltd.
- Inspection Date: 2019-04-16
- Product Type: drugs
- Office Name: Division of Human and Animal Food East V Compliance Branch
- Summary: An FDA inspection of Sumitomo Dainippon Pharma Co. Ltd. in Oita City, Japan, an API and Sterile API Manufacturer, revealed significant deficiencies in their sterile manufacturing processes. Observations included failures to establish and follow procedures to prevent microbiological contamination, inadequate environmental monitoring in aseptic processing areas, and a lack of validation for environmental monitoring media to recover microorganisms. These issues indicate a potential risk to the sterility and quality of their drug products.

## Related Documents

- [483 - 2025-07-11](https://www.keypedia.com/records/483/sumitomo-dainippon-pharma-co-ltd/0656e3d5-d284-4aa6-a7e2-95f9bddcde4d)

## Related Officers

- [Principal Consultant](https://www.keypedia.com/people/zhongren-wu/416f09a6-f225-4d23-a305-34f96a5c78f0)
- [SVP Consulting & Operations](https://www.keypedia.com/people/linda-f-murphy/a8b9737f-d5f4-4a36-8684-2fb050d008f2)

Company: https://www.keypedia.com/companies/sumitomo-dainippon-pharma-co-ltd/a14dd605-ff5f-4e7a-a71b-73f6eb72a9c6

Office: https://www.keypedia.com/offices/division-of-human-and-animal-food-east-v-compliance-branch/00f6013b-7c92-4daf-ae51-d47ab44bf1cb